Claims for Patent: 9,545,405

Summary for Patent: 9,545,405

Title:	Pyrrolo[2,3-D]pyrimidine derivatives
Abstract:	Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
Inventor(s):	Brown; Matthew Frank (Stonington, CT), Fenwick; Ashley Edward (Richland, MI), Flanagan; Mark Edward (Gales Ferry, CT), Gonzales; Andrea (Kalamazoo, MI), Johnson; Timothy Allan (Vicksburg, MI), Kaila; Neelu (Lexington, MA), Mitton-Fry; Mark J. (Granville, OH), Strohbach; Joseph Walter (Wentzville, MO), TenBrink; Ruth E. (Labadie, MO), Trzupek; John David (Medford, MA), Unwalla; Rayomand Jal (Bedford, MA), Vazquez; Michael L. (Billerica, MA), Parikh; Mihir D. (Groton, CT)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	14/691,606
Patent Claims:	1. A compound of formula I having the structure: ##STR00054## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is hydrogen or C.sub.1-C.sub.4 alkyl, wherein said alkyl is further optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, methoxy, amino, CF.sub.3, and C.sub.3-C.sub.6 cycloalkyl; X is selected from --NH-- and --CR.sub.aR.sub.b--, where (a) R.sub.a and R.sub.b are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl, (aryl)C.sub.1-C.sub.6 linear or branched chain alkyl, heteroaryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)heteroaryl, (heteroaryl)C.sub.1-C.sub.6 linear or branched chain alkyl, (heterocyclic)C.sub.1-C.sub.6 linear or branched chain alkyl, or (b) R.sub.a and R.sub.b together form a chain comprising --(CR.sub.cR.sub.d).sub.j--, where R.sub.c and R.sub.d are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, aryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)aryl, heteroaryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)heteroaryl, halo, CN, CF.sub.3, hydroxyl, CONH.sub.2, or SO.sub.2CH.sub.3; Y is -A-R.sup.5, where A is a bond, --(CH.sub.2).sub.k-- or --(CD.sub.2).sub.k- and R.sup.5 is C.sub.1-C.sub.6 linear or branched chain alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl, or --NR.sub.a'R.sub.b', or is an unsaturated, saturated or partially saturated monocyclic or bicyclic ring structure containing a total of four to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, wherein said alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl, or monocyclic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deuterium, halo, C.sub.1-C.sub.6 linear or branched chain alkyl, CN, hydroxyl, CF.sub.3, --OR.sub.e, --NR.sub.eR.sub.f, --S(O).sub.pR.sub.e and C.sub.3-C.sub.6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CONH.sub.2, and SO.sub.2CH.sub.3, where (a) R.sub.a' and R.sub.b' are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)aryl, heteroaryl, or (C.sub.1-C.sub.6 linear or branched chain alkyl)heteroaryl, where said alkyl and cycloalkyl may be optionally substituted with one or more R.sub.c', or (b) R.sub.a' and R.sub.b' together form a chain comprising --(CR.sub.c'R.sub.d').sub.j--, where R.sub.c' and R.sub.d' are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, aryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)aryl, heteroaryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)heteroaryl, halo, CN, hydroxyl, CF.sub.3, CONH.sub.2, --OR.sub.e, --NR.sub.eR.sub.f, or --S(O).sub.pR.sub.e; where R.sub.e and R.sub.f are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, or C.sub.3-C.sub.6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CF.sub.3, and CONH.sub.2; j is 2, 3, 4 or 5; k is 1, 2; 3, or 4; p is 0, 1 or 2; and, n is 1 or 2. 2. The compound of claim 1 which is a compound of formula IA having the structure: ##STR00055## or a pharmaceutically acceptable salt thereof, wherein Y is -A-R.sup.5, where A is a bond, --(CH.sub.2).sub.k-- or --(CD.sub.2).sub.k- and R.sup.5 is C.sub.1-C.sub.6 linear or branched chain alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl, or --NR.sub.a'R.sub.b', or is an unsaturated, saturated or partially saturated monocyclic or bicyclic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, wherein said alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl, or monocyclic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deuterium, halo, C.sub.1-C.sub.6 linear or branched chain alkyl, CN, hydroxyl, CF.sub.3, --OR.sub.e, --NR.sub.eR.sub.f, --S(O).sub.pR.sub.e and C.sub.3-C.sub.6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CONH.sub.2, and SO.sub.2CH.sub.3, where (a) R.sub.a' and R.sub.b' are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)aryl, heteroaryl, or (C.sub.1-C.sub.6 linear or branched chain alkyl)heteroaryl, where said alkyl and cycloalkyl may be optionally substituted with one or more R.sub.c', or (b) R.sub.a' and R.sub.b' together form a chain comprising --(CR.sub.c'R.sub.d').sub.j--, where R.sub.c' and R.sub.d' are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, aryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)aryl, heteroaryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)heteroaryl, halo, CN, hydroxyl, CF.sub.3, CONH.sub.2, --OR.sub.e, --NR.sub.eR.sub.f, or --S(O).sub.pR.sub.e; where R.sub.e and R.sub.f are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, or C.sub.3-C.sub.6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CF.sub.3, and CONH.sub.2; j is 2, 3, 4 or 5; k is 1, 2; 3, or 4; and, p is 0, 1 or 2. 3. A compound of claim 2 wherein A is a bond and R.sup.5 is a C.sub.1-C.sub.6 linear or branched chain alkyl, C.sub.3-C.sub.6 cycloalkyl or aryl. 4. A compound of claim 2 wherein A is a bond or --(CH.sub.2).sub.k--, and R.sup.5 is C.sub.3-C.sub.6 cycloalkyl wherein said C.sub.3-C.sub.6 cycloalkyl is further optionally substituted with one or more substituents selected from the group consisting of halo, C.sub.1-C.sub.6 linear or branched chain alkyl, and CN where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CONH.sub.2, and SO.sub.2CH.sub.3; where k is 1, 2, or 3. 5. A compound of claim 2 wherein A is a bond or --(CH.sub.2).sub.k--, and R.sup.5 is an unsaturated, saturated or partially saturated monocyclic or bicyclic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, wherein said alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl, or monocyclic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deuterium, halo, C.sub.1-C.sub.6 linear or branched chain alkyl, CN, hydroxyl, CF.sub.3, --NR.sub.a'R.sub.b', --OR.sub.e, --S(O).sub.pR.sub.e and C.sub.3-C.sub.6 cycloalkyl; where k is 1, 2, or 3. 6. The compound of claim 1 which is a compound of formula IB having the structure: ##STR00056## or a pharmaceutically acceptable salt thereof, wherein (a) R.sub.a' and R.sub.b' are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)aryl, heteroaryl, or (C.sub.1-C.sub.6 linear or branched chain alkyl)heteroaryl, where said alkyl and cycloalkyl may be optionally substituted with one or more R.sub.c; (b) R.sub.a' and R.sub.b' together form a chain comprising --(CR.sub.c'R.sub.d').sub.j--, where R.sub.c' and R.sub.d' are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, aryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)aryl, heteroaryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)heteroaryl, halo, CN, hydroxyl, CF.sub.3, CONH.sub.2, --OR.sub.e, --NR.sub.eR.sub.f, or --S(O).sub.pR.sub.e; where R.sub.e and R.sub.f are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, or C.sub.3-C.sub.6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CF.sub.3, and CONH.sub.2; or, (c) R.sub.a' and R.sub.b' together form an unsaturated, saturated or partially saturated monocyclic or bicyclic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, wherein said monocyclic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deuterium, halo, C.sub.1-C.sub.6 linear or branched chain alkyl, CN, hydroxyl, CF.sub.3, --NR.sub.eR.sub.f, --OR.sub.e, --S(O).sub.pR.sub.e and C.sub.3-C.sub.6 cycloalkyl; j is 2, 3, 4 or 5; and, p is 0, 1 or 2. 7. The compound of claim 1 which is a compound of formula IB having the structure: ##STR00057## or a pharmaceutically acceptable salt thereof, wherein R.sub.a' and R.sub.b' are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)aryl, heteroaryl, or (C.sub.1-C.sub.6 linear or branched chain alkyl)heteroaryl, where said alkyl and cycloalkyl may be optionally substituted with one or more R.sub.c. 8. The compound of claim 1 which is a compound of formula IB having the structure: ##STR00058## or a pharmaceutically acceptable salt thereof, wherein R.sub.a' and R.sub.b' together form a chain comprising --(CR.sub.c'R.sub.d').sub.j--, where R.sub.c' and R.sub.d' are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, aryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)aryl, heteroaryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)heteroaryl, halo, CN, hydroxyl, CF.sub.3, CONH.sub.2, --OR.sub.e, --NR.sub.eR.sub.f, or --S(O).sub.pR.sub.e; where R.sub.e and R.sub.f are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, or C.sub.3-C.sub.6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CF.sub.3, and CONH.sub.2; and, j is 2, 3, 4 or 5; and, p is 0, 1 or 2. 9. The compound of claim 1 which is a compound of formula IB having the structure: ##STR00059## or a pharmaceutically acceptable salt thereof, wherein R.sub.a' and R.sub.b' together form an unsaturated, saturated or partially saturated monocyclic or bicyclic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, wherein said monocyclic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deuterium, halo, C.sub.1-C.sub.6 linear or branched chain alkyl, CN, hydroxyl, CF.sub.3, --NR.sub.eR.sub.f, --OR.sub.e, --S(O).sub.pR.sub.e and C.sub.3-C.sub.6 cycloalkyl; and, p is 0, 1 or 2. 10. The compound of claim 1 which is a compound of formula IC having the structure: ##STR00060## or a pharmaceutically acceptable salt thereof, wherein (a) R.sub.a' and R.sub.b' are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)aryl, heteroaryl, or (C.sub.1-C.sub.6 linear or branched chain alkyl)heteroaryl, where said alkyl and cycloalkyl may be optionally substituted with one or more R.sub.c; (b) R.sub.a' and R.sub.b' together form a chain comprising --(CR.sub.c'R.sub.d').sub.j--, where R.sub.c' and R.sub.d' are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, aryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)aryl, heteroaryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)heteroaryl, halo, CN, hydroxyl, CF.sub.3, CONH.sub.2, --OR.sub.e, --NR.sub.eR.sub.f, or --S(O).sub.pR.sub.e; where R.sub.e and R.sub.f are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, or C.sub.3-C.sub.6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CF.sub.3, and CONH.sub.2; or, (c) R.sub.a' and R.sub.b' together form an unsaturated, saturated or partially saturated monocyclic or bicyclic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, wherein said monocyclic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deuterium, halo, C.sub.1-C.sub.6 linear or branched chain alkyl, CN, hydroxyl, CF.sub.3, --NR.sub.eR.sub.f, --OR.sub.e, --S(O).sub.pR.sub.e and C.sub.3-C.sub.6 cycloalkyl; j is 2, 3, 4 or 5; and, p is 0, 1 or 2. 11. The compound of claim 1 which is a compound of formula IC having the structure: ##STR00061## or a pharmaceutically acceptable salt thereof, wherein R.sub.a' and R.sub.b' are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)aryl, heteroaryl, or (C.sub.1-C.sub.6 linear or branched chain alkyl)heteroaryl, where said alkyl and cycloalkyl may be optionally substituted with one or more R.sub.c. 12. The compound of claim 1 which is a compound of formula IC having the structure: ##STR00062## or a pharmaceutically acceptable salt thereof, wherein R.sub.a' and R.sub.b' together form a chain comprising --(CR.sub.c'R.sub.d').sub.j--, where R.sub.c' and R.sub.d' are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, aryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)aryl, heteroaryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)heteroaryl, halo, CN, hydroxyl, CF.sub.3, CONH.sub.2, --OR.sub.e, --NR.sub.eR.sub.f, or --S(O).sub.pR.sub.e; where R.sub.e and R.sub.f are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, or C.sub.3-C.sub.6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CF.sub.3, and CONH.sub.2; j is 2, 3, 4 or 5; and, p is 0, 1 or 2. 13. The compound of claim 1 which is a compound of formula IC having the structure: ##STR00063## or a pharmaceutically acceptable salt thereof, wherein R.sub.a' and R.sub.b' together form an unsaturated, saturated or partially saturated monocyclic or bicyclic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, wherein said monocyclic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deuterium, halo, C.sub.1-C.sub.6 linear or branched chain alkyl, CN, hydroxyl, CF.sub.3, --NR.sub.eR.sub.f, --OR.sub.e, --S(O).sub.pR.sub.e and C.sub.3-C.sub.6 cycloalkyl; and, p is 0, 1 or 2. 14. The compound of claim 1 which is a compound of formula ID having the structure: ##STR00064## or a pharmaceutically acceptable salt thereof, wherein Y is -AR.sup.5, where A is a bond or --(CH.sub.2).sub.k--, and R.sup.5 is C.sub.1-C.sub.6 linear or branched chain alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl, or is an unsaturated, saturated or partially saturated monocyclic or bicyclic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, wherein said alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl, or monocyclic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deuterium, halo, C.sub.1-C.sub.6 linear or branched chain alkyl, CN, hydroxyl, CF.sub.3, --NR.sub.a'R.sub.b', --OR.sub.e, --S(O).sub.pR.sub.e and C.sub.3-C.sub.6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CONH.sub.2, and SO.sub.2CH.sub.3, where (a) R.sub.a' and R.sub.b' are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl, (aryl)C.sub.1-C.sub.6 linear or branched chain alkyl, heteroaryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)heteroaryl, (heteroaryl)C.sub.1-C.sub.6 linear or branched chain alkyl, (heterocyclic)C.sub.1-C.sub.6 linear or branched chain alkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more R.sub.c', or (b) R.sub.a' and R.sub.b' together form a chain comprising --(CR.sub.c'R.sub.d').sub.j--, where R.sub.c' and R.sub.d' are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, aryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)aryl, heteroaryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)heteroaryl, halo, CN, hydroxyl, CF.sub.3, CONH.sub.2, --OR.sub.e, --NR.sub.eR.sub.f, or --S(O).sub.pR.sub.e; where R.sub.e and R.sub.f where are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, or C.sub.3-C.sub.6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CF.sub.3, and CON H.sub.2; j is 2, 3, 4 or 5; k is 1, 2, or 3; and, p is 0, 1 or 2. 15. The compound of claim 1 which is a compound of formula ID having the structure: ##STR00065## or a pharmaceutically acceptable salt thereof, wherein Y is -AR.sup.5, where A is a bond or --(CH.sub.2).sub.k--, and R.sup.5 is C.sub.1-C.sub.6 linear or branched chain alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl, or is an unsaturated, saturated or partially saturated monocyclic or bicyclic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, wherein said alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl, or monocyclic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deuterium, halo, C.sub.1-C.sub.6 linear or branched chain alkyl, CN, hydroxyl, CF.sub.3, --NR.sub.a'R.sub.b', --OR.sub.e, --S(O).sub.pR.sub.e and C.sub.3-C.sub.6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CON H.sub.2, and SO.sub.2CH.sub.3, where R.sub.a' and R.sub.b' are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl, (aryl)C.sub.1-C.sub.6 linear or branched chain alkyl, heteroaryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)heteroaryl, (heteroaryl)C.sub.1-C.sub.6 linear or branched chain alkyl, (heterocyclic)C.sub.1-C.sub.6 linear or branched chain alkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more R.sub.c', k is 1, 2, or 3; and, p is 0, 1 or 2. 16. The compound of claim 1 which is a compound of formula ID having the structure: ##STR00066## or a pharmaceutically acceptable salt thereof, wherein Y is -AR.sup.5, where A is a bond or --(CH.sub.2).sub.k--, and R.sup.5 is C.sub.1-C.sub.6 linear or branched chain alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl, or is an unsaturated, saturated or partially saturated monocyclic or bicyclic ring structure containing a total of five to eleven atoms having one to three heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, wherein said alkyl, C.sub.3-C.sub.6 cycloalkyl, aryl, or monocyclic or bicyclic ring structure is further optionally substituted with one or more substituents selected from the group consisting of deuterium, halo, C.sub.1-C.sub.6 linear or branched chain alkyl, CN, hydroxyl, CF.sub.3, --NR.sub.a'R.sub.b', --OR.sub.e, --S(O).sub.pR.sub.e and C.sub.3-C.sub.6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CONH.sub.2, and SO.sub.2CH.sub.3, where R.sub.a' and R.sub.b' together form a chain comprising --(CR.sub.c'R.sub.d').sub.j--, where R.sub.c' and R.sub.d' are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, aryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)aryl, heteroaryl, (C.sub.1-C.sub.6 linear or branched chain alkyl)heteroaryl, halo, CN, hydroxyl, CF.sub.3, CONH.sub.2, --OR.sub.e, --NR.sub.eR.sub.f, or --S(O).sub.pR.sub.e; where R.sub.e and R.sub.f where are independently hydrogen, deuterium, C.sub.1-C.sub.6 linear or branched chain alkyl, or C.sub.3-C.sub.6 cycloalkyl, where said alkyl and cycloalkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, CF.sub.3, and CONH.sub.2; j is 2, 3, 4 or 5; k is 1, 2, or 3; and, p is 0, 1 or 2. 17. The compound of claim 1 which is a compound of formula ID having the structure: ##STR00067## or a pharmaceutically acceptable salt thereof, wherein Y is -AR.sup.5, where A is a bond or --(CH.sub.2).sub.k--, and R.sup.5 is C.sub.1-C.sub.6 linear or branched chain alkyl, where said alkyl may be optionally substituted with one or more substituents selected from the group consisting of halo, CN, hydroxyl, and SO.sub.2CH.sub.3; and, k is 1, 2, or 3. 18. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.